UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD

COALITION FOR AFFORDABLE DRUGS VIII, LLC Petitioner,

v.

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Patent Owner


Case: IPR2015-01836
Patent No. 7,932,268

UPDATED LIST OF PATENT OWNER'S EXHIBITS




PATENT OWNER'S LIST OF EXHIBITS

Ex. 2001	University of Pennsylvania Patent License Agreement (May 19,
EA. 2001	2006)
	NDA #203858, Sponsor's Background Package For the
Ex. 2002	Endocrinologic and Metabolic Drugs Advisory Committee
	Meeting, Advisory Committee Briefing Materials (Oct. 17, 2012)
	ClinicalTrials.gov: Safety, Tolerability, and Efficacy of
	Microsomal Triglyceride Protein (MTP) Inhibitor, available at
Ex. 2003	https://clinicaltrials.gov/ct2/show/NCT01556906?term=NCT0155
	6906&rank=1
	Marina Cuchel et al., Inhibition of Microsomal Triglyceride
Ex. 2004	Transfer Protein in Familial Hypercholesterolemia, 356 (2) N.
	ENG. J. MED. 148-56 (Jan. 11, 2007).
Ex. 2005	U.S. Appl. No. 14/075,483, Amendment and Response to Final
	Office Action (Nov. 30, 2015)
	FDA News Release, FDA approves new orphan drug for rare
	cholesterol disorder, available at
Ex. 2006	http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncement
	s/ucm333285.htm (Dec. 26, 2012)
	Marina Cuchel et al., Efficacy and safety of a microsomal
	triglyceride transfer protein inhibitor in patients with homozygous
Ex. 2007	familial hypercholesterolemia: a single-arm, open-label, phase 3
	study, 381 THE LANCET 40-46 (Jan. 5, 2013)
	Joseph Walker et al., New Hedge Fund Strategy: Dispute the
	Patent, Short the Stock, THE WALL STREET JOURNAL (Apr. 7,
	2015), available at
Ex. 2008	http://www.wsj.com/articles/hedgefundmanagerkylebasschallenge
	sjazzpharmaceuticalspatent1428417408
Ex. 2009	Intentionally Left Blank
	Patentee's Observations in reply to the Notice of Opposition by
Ex. 2010	Dr. Evan Stein, European Patent No. 1 725 234
	D1. Lvan Stein, European I atent No. 1 /23 234



Γ	
Ex. 2011	The Pink Sheet, MTP inhibitor research discontinued (July 31,
	2000)
Ex. 2012	Aegerion Pharmaceuticals, Inc., U.S. Securities and Exchange
	Commission, Form 10-K (March 2, 2015)
Ex. 2013	Aegerion Pharmaceuticals, Inc., U.S. Securities and Exchange
	Commission, Form 10-K (March 18, 2013)
	Aegerion Pharmaceuticals, Inc., Third Quarter 2015 Earnings
	Conference Call, available at
Ex. 2014	http://files.shareholder.com/downloads/AEGR/0x0x860375/8F9C
	1576-D084-454D-BBCF-
	C656C341E238/AEGR_Q3_15_Slides_Final.pdf (Nov. 9, 2015)
Ex. 2015	JUXTAPID label (2012)
	Center For Drug Evaluation And Research, Application Number
Ex. 2016	203858Orig1s00, Summary Basis for Regulatory Action (Dec. 21,
	2012)
	Declaration of Nicholas K. Mitrokostas in support of Patent
Ex. 2017	Owner's Motion for <i>Pro Hac Vice</i> Admission of Nicholas K.
	Mitrokostas Under 37 C.F.R. § 42.10(c)



CERTIFICATION OF SERVICE

The undersigned hereby certifies that the foregoing "UPDATED LIST OF

PATENT OWNER'S EXHIBITS" was served electronically via e-mail on May 5,

2016 on the following:

Dr. Gregory Gonsalves 2216 Beacon Lane Falls Church, Virginia 22043 (571) 419-7252 gonsalves@gonsalveslawfirm.com

Christopher Casieri McNeely, Hare & War LLP 12 Roszel Road, Suite C104 Princeton, NJ 08540 (609) 731-3668 chris@miplaw.com

Counsel for Petitioner Coalition for Affordable Drugs VIII, LLC

Dated: May 5, 2016 /April E. Weisbruch/

April E. Weisbruch

